Search Results - "DOĞU, Figen"

Refine Results
  1. 1
  2. 2
  3. 3

    Clinical Features and Outcomes of 23 Patients with Wiskott- Aldrich Syndrome: A Single-Center Experience by Haskoloğlu, Şule, Öztürk, Ayşenur, Öztürk, Gökcan, Kostel Bal, Sevgi, İslamoğlu, Candan, Baskın, Kübra, Ceylaner, Serdar, Tufan Satıroğlu, Lale, Doğu, Figen, İkincioğulları, Aydan

    Published in Turkish journal of haematology (19-11-2020)
    “…Objective: Wiskott-Aldrich syndrome (WAS) is an X-linked primary immune deficiency characterized by microthrombocytopenia, eczema, and recurrent infections. We…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13

    T Regulatory Cells in Children with Atopic Dermatitis by Çiftçi, Ömer, Haskoloğlu, Zehra Şule, Güloğlu, Deniz, Çipe, Funda, Çiftçi, Aylin, Köse, Kenan, Doğu, Figen, İkincioğulları, Aydan

    “…Objectives: The aim of this study was to examine peripheral blood CD4+CD25high+FOXP3+ regulatory T (Treg) cell levels in children with atopic dermatitis (AD)…”
    Get full text
    Journal Article
  14. 14

    Clinical Features and HSCT Outcome for SCID in Turkey by Ikinciogullari, Aydan, Cagdas, Deniz, Dogu, Figen, Tugrul, Tuba, Karasu, Gulsum, Haskologlu, Sule, Aksoylar, Serap, Uygun, Vedat, Kupesiz, Alphan, Yildiran, Alisan, Gursel, Orhan, Ates, Can, Elhan, Atilla, Kansoy, Savas, Yesilipek, Akif, Tezcan, Ilhan

    Published in Journal of clinical immunology (01-04-2019)
    “…Severe combined immunodeficiency (SCID) is the most serious PID, characterized by T cell lymphopenia and lack of antigen-specific T cell and B cell immune…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Outcome of treosulfan‐based reduced‐toxicity conditioning regimens for HSCT in high‐risk patients with primary immune deficiencies by Haskoloğlu, Şule, Köstel Bal, Sevgi, İslamoğlu, Candan, Altun, Demet, Kendirli, Tanıl, Doğu, Esin Figen, İkincioğulları, Aydan

    Published in Pediatric transplantation (01-11-2018)
    “…Introduction HSCT is the curative therapeutic option in PIDs. Due to the increase in survival rates, reduced‐toxicity conditioning regimens with treosulfan…”
    Get full text
    Journal Article